MRK — Merck & Co., Inc.

Summary of Merck & Co., Inc. (MRK) Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Total Revenues: $16.4 billion, up 5% (4% excluding foreign exchange).
• KEYTRUDA Sales: Increased 5% to $8.4 billion, driven by uptake in earlier-stage cancers and metastatic indications.
• Gross Margin: 79.7%, down 1.1 percentage points due to higher inventory reserves.
• Operating Expenses: $6.8 billion, with a notable decrease in business development charges.
• Earnings Per Share (EPS): $2.04.
• 2026 Guidance: Expected revenues between $65.5 billion and $67 billion (1% to 3% growth), EPS projected at $5 to $5.15.

2. Strategic Updates and Business Highlights

• Product Launches: Successful launches in cardiometabolic and respiratory segments, including enlicitide and Winravir.
• Acquisitions: Completed acquisition of Sidera Therapeutics, enhancing the infectious disease portfolio with MK1406, a long-acting antiviral candidate.
• Pipeline Progress: Over 20 potential new growth drivers, with 10 programs expected to be clinically derisked in the next two years.
• Oncology Developments: Continued positive results for KEYTRUDA and new combinations, including recent approvals for bladder cancer treatments.

3. Forward Guidance and Outlook

• Long-term Potential: Management highlighted a $70 billion non-risk adjusted commercial opportunity by the mid-2030s, significantly boosted from previous estimates.
• Growth Drivers: Anticipated contributions from new product launches, strong oncology performance, and animal health growth.
• Challenges: Expected headwinds from generic competition, particularly affecting the Januvia family and other products.

4. Bad News, Challenges, or Points of Concern

• Generic Competition: Anticipated $2.5 billion impact from generics and IRA price setting, particularly affecting key products like Januvia and Ligevrio.
• Gardasil Sales Decline: Gardasil sales decreased 35% due to lower demand in key markets.
• Regulatory and Competitive Pressures: Concerns about the timing of KEYTRUDA's loss of exclusivity (LOE) and the competitive landscape for new therapies.

5. Notable Q&A Insights

• KEYTRUDA IP Strategy: Management expressed confidence in defending additional patents beyond the expected 2028 expiration, potentially extending protection to 2029.
• HIV Treatment Innovations: Discussion on the significance of a two-drug regimen (islatravir and doravirine) compared to standard three-drug therapies, highlighting unmet needs in the market.
• Winravir's Market Position: Emphasized as reshaping the standard of care in pulmonary arterial hypertension (PAH) with a differentiated mechanism.
• Pipeline Confidence: Executives reiterated strong confidence in the pipeline's potential to deliver sustainable growth post-KEYTRUDA LOE, with a focus on upcoming clinical milestones.

Overall, Merck reported solid financial results and strategic advancements while acknowledging challenges from competition and regulatory pressures. The outlook remains cautiously optimistic, with significant growth opportunities in their pipeline and new product launches.